PYX-201 is named as a drug or biological intervention in 2 clinical trials in our USA and UK trial registers, 2 of which are recruiting. The lead sponsor is Pyxis Oncology, Inc. Registered phases: Phase 1 and Phase 1/2. Conditions studied include Solid Tumor; Advanced Solid Tumor; Advanced Solid Tumors.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06795412 | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors Advanced Solid Tumors |
Phase 1/2 | Recruiting |
| NCT05720117 | A Study of PYX-201 in Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Advanced Solid Tumor |
Phase 1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Solid Tumor | 1 |
| Advanced Solid Tumor | 1 |
| Advanced Solid Tumors | 1 |
| Lead sponsor | Trials |
|---|---|
| Pyxis Oncology, Inc | 2 |
| Register | PYX-201 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PYX-201 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PYX-201 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.